Orthofix Medical (OFIX) 10-Q 18 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	11-May-15
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	FALSE
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Trading Symbol	OFIX
Entity Registrant Name	ORTHOFIX INTERNATIONAL N V
Entity Central Index Key	884624
Current Fiscal Year End Date	-19
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		18,766,158

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$29,784	$36,815
Restricted cash	27,253	34,424
Trade accounts receivable, less allowance for doubtful accounts of $6,831 and $7,285 at March 31, 2015 and December 31, 2014, respectively	58,535	61,358
Inventories	56,709	59,846
Deferred income taxes	36,913	37,413
Prepaid expenses and other current assets	25,840	26,552
Total current assets	235,034	256,408
Property, plant and equipment, net	46,737	48,549
Patents and other intangible assets, net	5,888	7,152
Goodwill	53,565	53,565
Deferred income taxes	18,139	18,541
Other long-term assets	27,351	8,970
Total assets	386,714	393,185
Current liabilities:
Trade accounts payable	16,322	13,223
Other current liabilities	53,083	53,220
Total current liabilities	69,405	66,443
Deferred income taxes		229
Other long-term liabilities	26,769	26,886
Total liabilities	96,174	93,558
Contingencies (Note 11)
Shareholders’ equity:
Common shares $0.10 par value; 50,000,000 shares authorized; 18,757,361 and 18,611,495 issued and outstanding as of March 31, 2015 and December 31, 2014, respectively	1,876	1,861
Additional paid-in capital	236,260	232,788
Retained earnings	56,981	65,360
Accumulated other comprehensive loss	-4,577	-382
Total shareholders’ equity	290,540	299,627
Total liabilities and shareholders’ equity	$386,714	$393,185

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Statement Of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$6,831	$7,285
Common shares, par value	$0.10	$0.10
Common shares, authorized	50,000,000	50,000,000
Common shares, issued	18,757,361	18,611,495
Common shares, outstanding	18,757,361	18,611,495

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Product sales	$76,832	$88,300
Marketing service fees	12,930	11,714
Net sales	89,762	100,014
Cost of sales	19,339	26,773
Gross profit	70,423	73,241
Operating expenses
Sales and marketing	44,285	41,171
General and administrative	21,164	17,276
Research and development	5,845	5,933
Amortization of intangible assets	405	584
Costs related to the accounting review and restatements	5,916	8,306
Total operating expenses	77,615	73,270
Operating loss	-7,192	-29
Other income and expense
Interest expense, net	-272	-468
Other income (expense)	691	-272
Total other income (expense)	419	-740
Loss before income taxes	-6,773	-769
Income tax expense	-964	-1,179
Net loss from continuing operations	-7,737	-1,948
Discontinued operations
Loss from discontinued operations	-781	-794
Income tax benefit	139	234
Net loss from discontinued operations	-642	-560
Net loss	-8,379	-2,508
Net loss per common share—basic:
Net loss from continuing operations	($0.41)	($0.11)
Net loss from discontinued operations	($0.04)	($0.03)
Net loss per common share—basic	($0.45)	($0.14)
Net loss per common share—diluted:
Net loss from continuing operations	($0.41)	($0.11)
Net loss from discontinued operations	($0.04)	($0.03)
Net loss per common share—diluted	($0.45)	($0.14)
Weighted average number of common shares:
Basic	18,731,985	18,197,363
Diluted	18,731,985	18,197,363
Other comprehensive (loss) income:
Unrealized gain on cross-currency swap, net of tax	665	103
Foreign currency translation adjustment	-4,860	376
Comprehensive loss	($12,574)	($2,029)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net cash provided by (used in) operating activities	$4,941	($10,212)
Cash flows from investing activities:
Capital expenditures for property, plant and equipment	-5,074	-3,691
Capital expenditures for intangible assets	-39	-46
Net proceeds from sale of assets	4,800
Purchase of debt securities	-15,250
Net proceeds from sale of other investments		32
Net cash used in investing activities	-15,563	-3,705
Cash flows from financing activities:
Net proceeds from issuance of common shares	1,710	5,542
Changes in restricted cash	7,171	4,502
Excess income tax benefit on employee stock-based awards	57	29
Net cash provided by financing activities	8,938	10,073
Effect of exchange rate changes on cash	-5,347	37
Net decrease in cash and cash equivalents	-7,031	-3,807
Cash and cash equivalents at the beginning of the period	36,815	28,924
Cash and cash equivalents at the end of the period	$29,784	$25,117

Nature_of_operations_basis_of_

Nature of operations, basis of presentation and recently issues accounting pronouncements	3 Months Ended
	Mar. 31, 2015
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Abstract]
Nature of operations, basis of presentation and recently issues accounting pronouncements	1. Nature of operations, basis of presentation and recently issues accounting pronouncements
	Nature of operations
	Orthofix International N.V. (together with its subsidiaries, the “Company”) is a diversified, global medical device company focused on developing and delivering innovative repair and regenerative technologies to the spine and orthopedic markets. The Company is comprised of four reportable segments: BioStim, Biologics, Extremity Fixation and Spine Fixation supported by Corporate activities.
	Basis of presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair statement have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Operating results for the three months ended March 31, 2015, are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. The balance sheet at December 31, 2014, has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates including those related to contractual allowances, doubtful accounts, inventories, potential goodwill and intangible asset impairment, income taxes, and shared-based compensation. Actual results could differ from these estimates. As permitted under U.S. GAAP, interim accounting for certain expenses, including income taxes, are based on full year forecasts. For interim financial reporting purposes, income taxes are recorded based upon estimated annual effective income tax rates taking into consideration discrete items occurring in a quarter.
	Recently issued accounting standards
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Components of an Entity. The ASU amends the definition of a discontinued operation and also provides new disclosure requirements for disposals meeting the definition, and for those that do not meet the definition, of a discontinued operation. Under the new guidance, a discontinued operation may include a component or a group of components of an entity, or a business or nonprofit activity that has been disposed of or is classified as held for sale, and represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The ASU also expands the scope to include the disposals of equity method investments and acquired businesses held for sale. The guidance will be effective prospectively for interim and annual periods beginning on or after December 15, 2014, with early adoption permitted. The adoption of the guidance by the Company did not have a material impact on its consolidated financial statements.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	2. Inventories
	The Company’s inventories are primarily stated at standard cost, which approximates actual cost determined on a first-in, first-out basis. Work-in-process and finished products include material, labor and production overhead costs. Finished products include field inventory which represents immediately saleable finished products that are in the possession of the Company’s direct sales representatives, and consignment inventory which represents immediately saleable finished products located at third party customers, such as distributors and hospitals. Deferred cost of sales result from transactions where the Company has shipped product or performed services for which all revenue recognition criteria have not been met. Once the revenue recognition criteria have been met, both the deferred revenues and associated cost of sales are recognized.
	Inventories were as follows:
	(U.S. Dollars, in thousands)	March 31,		December 31,
		2015		2014
	Raw materials	$	3,868	$	3,879
	Work-in-process		4,441		4,830
	Finished products		42,445		45,612
	Deferred cost of sales		5,955		5,525
	Total inventory	$	56,709	$	59,846

Longterm_debt

Long-term debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Long-term debt	3. Long-term debt
	On August 30, 2010, the Company’s wholly-owned U.S. holding company, Orthofix Holdings, Inc. (“Orthofix Holdings”) entered into a Credit Agreement (the “Credit Agreement”) with certain domestic direct and indirect subsidiaries of the Company (the “Guarantors”), JPMorgan Chase Bank, N.A., as Administrative Agent, RBS Citizens, N.A., as Syndication Agent, and certain lender parties thereto.
	The Credit Agreement initially provided for a five year, $200 million secured revolving credit facility (the “Revolving Credit Facility”), and a five year, $100 million secured term loan facility (the “Term Loan Facility,” and together with the Revolving Credit Facility, the “Credit Facilities”). On January 15, 2015, at the Company’s request, the lenders agreed to reduce the available capacity under the Revolving Credit Facility to $100 million.
	As of March 31, 2015, and December 31, 2014, there was no outstanding principal under either the Term Loan Facility or the Revolving Credit Facility.  Any outstanding balance on the Revolving Credit Facility arising in the event that we draw funds in the future under such facility would be due on August 30, 2015.
	The amount of net assets of Orthofix Holdings and its subsidiaries that we classify as “restricted” (due to restrictions on the use of such assets pursuant to the terms of the agreement) as of March 31, 2015, and December 31, 2014, is $184.1 million and $181.8 million, respectively. In addition, the Credit Agreement contains restrictions on the Company and subsidiaries that are not parties to the Credit Facilities accessing cash held by Orthofix Holdings, Inc. and its subsidiaries (by way of dividend or otherwise). All of the Company’s subsidiaries that are parties to the Credit Agreement generally have access to this cash for operational and debt repayment purposes. The amount of cash of the Company and its subsidiaries that we classify as “restricted” due to these restrictions as of March 31, 2015, and December 31, 2014, was $27.3 million and $34.4 million, respectively.
	The Company had no borrowings and an unused available line of credit of €5.8 million ($6.2 million and $7.0 million) at March 31, 2015 and December 31, 2014, respectively, on its Italian line of credit. This unsecured line of credit provides the Company the option to borrow amounts in Italy at rates which are determined at the time of borrowing.

Derivative_instruments

Derivative instruments	3 Months Ended
	Mar. 31, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative instruments	4. Derivative instruments
	The tables below disclose the types of derivative instruments the Company owns, the classifications and fair values of these instruments within the balance sheet, and the amount of gain (loss) recognized in other comprehensive loss (“OCI”).  The ineffective portions of these instruments totaling $3.0 million and $0.1 million for the three months ended March 31, 2015 and 2014, respectively, are recognized in other income (expense).
	(U.S. Dollars, in thousands)	Fair value: favorable			Balance sheet location
	As of March 31, 2015	(unfavorable)
	Cross-currency swap	$	6,161		Other long-term assets
	Warrants	$	311		Other long-term assets
	As of December 31, 2014
	Cross-currency swap	$	2,504		Other long-term assets
	Warrants	$	321		Other long-term assets
		Three Months Ended
		March 31,
	(U.S. Dollars, in thousands)	2015			2014
	Cross-currency swap unrealized gain recorded in other	$	669		$	103
	comprehensive loss, net of taxes
	Warrants unrealized loss recorded in other	$	(4	)	$	—
	comprehensive loss, net of taxes

Fair_value_measurements

Fair value measurements	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair value measurements	5. Fair value measurements
	The fair value of the Company’s financial assets and liabilities on a recurring basis were as follows:
	(U.S. Dollars in thousands)	Balance			Level 1		Level 2			Level 3
		March 31,
		2015
	Assets
	Collective trust funds	$	1,679		$	—	$	1,679		$	—
	Treasury securities		507			507		—			—
	Certificates of deposit		1,260			1,260		—			—
	Derivative securities		6,472			—		6,472			—
	Equity securities		1,457			—		1,457			—
	Debt securities		15,000			—		—			15,000
	Total	$	26,375		$	1,767	$	9,608		$	15,000
	Liabilities
	Deferred compensation plan	$	(1,488	)	$	—	$	(1,488	)	$	—
	Total	$	(1,488	)	$	—	$	(1,488	)	$	—
	(U.S. Dollars in thousands)	Balance			Level 1		Level 2			Level 3
		December 31,
		2014
	Assets
	Collective trust funds	$	1,696		$	—	$	1,696		$	—
	Treasury securities		586			586		—			—
	Certificates of deposit		1,510			1,510		—			—
	Derivative securities		2,825			—		2,825			—
	Equity securities		1,457			—		1,457			—
	Total	$	8,074		$	2,096	$	5,978		$	—
	Liabilities
	Deferred compensation plan	$	(1,886	)	$	—	$	(1,886	)	$	—
	Total	$	(1,886	)	$	—	$	(1,886	)	$	—
	Debt Securities
	On March 4, 2015, the Company entered into an Option Agreement (the “Option Agreement”) with eNeura, Inc. (“eNeura”), a privately held medical technology company that is developing devices for the treatment of migraines. The Option Agreement provides the Company with an exclusive option to acquire eNeura (the “Option”) during the 18-month period following the grant of the Option. In consideration for the Option, (i) the Company paid a non-refundable $0.3 million fee to eNeura, and (ii) eNeura issued a Convertible Promissory Note (the “eNeura Note”) to the Company. The principal amount of the eNeura Note is $15.0 million and interest accrues at 8.0%. The eNeura Note will mature on the earlier of (i) March 4, 2019, or (ii) exercise of the Option. The investment in eNeura is recorded in other long-term assets, and is classified as an available for sale debt security, for which the fair value is based upon significant unobservable inputs, requiring the Company to develop its own assumptions, therefore the Company has categorized this asset as a Level 3 financial asset. Given the date of the transaction, as of March 31, 2015, the Company believes the initial amount of the investment approximates fair value.
	The following table provides a reconciliation of the beginning and ending balances for the debt securities measured at fair value using significant unobservable inputs (Level 3):
	(U.S. Dollars in thousands)	2015
	Balance at January 1	$	—
	Additions to debt securities		15,000
	Balance at March 31	$	15,000

Accumulated_other_comprehensiv

Accumulated other comprehensive loss	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Accumulated other comprehensive loss	6. Accumulated other comprehensive loss
	Accumulated other comprehensive loss is comprised of foreign currency translation adjustments, the effective portion of the gain (loss) on the Company’s cross-currency swap, which is designated and accounted for as a cash flow hedge and the unrealized gain (loss) on warrants. The components of and changes in accumulated other comprehensive loss were as follows:
	(U.S. Dollars, in thousands)		Foreign Currency			Change		Accumulated Other
			Translation Adjustments			in		Comprehensive Loss
						Fair Value
	Balance at December 31, 2014		$	(482	)	$	100	$	(382	)
	Unrealized gain on cross-currency swap and warrants,			—			665		665
	net of tax of $435
	Foreign currency translation adjustment (1)			(4,860	)		—		(4,860	)
	Balance at March 31, 2015		$	(5,342	)	$	765	$	(4,577	)
	-1	As the unremitted earnings generally remain indefinitely reinvested in the non U.S. dollar denominated foreign subsidiaries, no deferred taxes are recognized on the related foreign currency translation adjustment.

Earnings_per_share

Earnings per share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings per share	7. Earnings per share
	For the three months ended March 31, 2015 and 2014, there were no adjustments to net loss for purposes of calculating basic and diluted net loss available to common shareholders. The following is a reconciliation of the weighted average shares used in the basic and diluted net loss per common share computations.
		Three Months Ended
		March 31,
		2015		2014
	Weighted average common shares-basic		18,731,985		18,197,363
	Effect of dilutive securities:
	Unexercised stock options net of treasury share		—		—
	repurchase
	Weighted average common shares-diluted		18,731,985		18,197,363
	Options to purchase shares of common stock with exercise prices in excess of the average market price of common shares are not included in the computation of diluted earnings per share. There were 894,565 and 1,691,203 outstanding options not included in the diluted earnings per share computation for the three months ended March 31, 2015 and 2014, respectively, because the inclusion of these options was antidilutive.
	Due to the Company being in a net loss position for the three months ended March 31, 2015 and 2014, no adjustment has been made for potentially dilutive shares totaling 182,266 and 30,719, respectively, for any common stock equivalents as their effects would be antidilutive.

Sharebased_compensation

Share-based compensation	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-based compensation	8. Share-based compensation
	All share-based compensation costs are measured at the grant date, based on the estimated fair value of the award, and are recognized as expense in the condensed consolidated statements of operations over the requisite service period.
	The following table shows the detail of share-based compensation by line item in the condensed consolidated statements of operations:
		Three Months Ended
		March 31,
	(U.S. Dollars, in thousands)	2015		2014
	Cost of sales	$	111	$	29
	Sales and marketing		306		444
	General and administrative		1,269		642
	Research and development		91		72
	Total	$	1,777	$	1,187
	On June 30, 2014, the Company granted restricted share awards to executive employees. Vesting is based on achieving earnings targets in two consecutive rolling four quarter periods. As of March 31, 2015, no expense has been recognized for these contingent restricted share awards.
	During the three months ended March 31, 2015 and 2014, there were 153,367 and 263,575 shares, respectively, of common stock issued related to stock purchase plan issuances, stock option exercises and the vesting of restricted stock awards.

Income_taxes

Income taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income taxes	9. Income taxes
	The Company recognized a $1.0 million and $1.2 million provision for income tax on continuing operations which reflects an effective tax rate of (14.2)% and (153.3)% on pre-tax income for the three months ended March 31, 2015 and 2014, respectively. Excluding the impact of various discrete charges, the effective tax rate on continuing operations was (9.2)% and (68.5)% for the first three months of 2015 and 2014, respectively. The principal factors affecting the Company’s March 31, 2015 effective tax rate were the Company’s mix of earnings among various tax jurisdictions, state taxes, current period losses in certain jurisdictions for which the Company does not currently provide a tax benefit and variations in the customary relationship between income tax expense and pretax earnings.
	As of March 31, 2015 and December 31, 2014, the Company’s unrecognized tax benefit was $15.6 million. The Company had approximately $0.5 million accrued for payment of interest and penalties as of March 31, 2015 and December 31, 2014. It is reasonably possible that the amount of the unrecognized benefit with respect to certain of our unrecognized tax positions will significantly increase or decrease within the next 12 months. These changes may be the result of settlements of ongoing audits, competent authority proceedings or other events. At this time, an estimate of the range of the reasonably possible outcomes cannot be made.

Business_segment_information

Business segment information	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Business segment information	10. Business segment information
	The Company has four strategic business units (“SBUs”), which are comprised of BioStim, Biologics, Extremity Fixation, and Spine Fixation supported by Corporate activities. The primary metric used in managing the Company is net margin, which is defined as gross profit less sales and marketing expense. The Company neither discretely allocates assets, other than goodwill, to its operating segments nor evaluates the operating segments using discrete asset information. Accordingly, our segment information has been prepared based on our four SBUs reporting segments.
	The table below presents net sales for continuing operations by SBU reporting segment. Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution®, Trinity ELITE® and Versashield™ in our Biologics segment.
		Net Sales by SBU
		Three Months Ended March 31,
	(U.S. Dollars, in thousands)	2015			2014			Reported			Constant
								Increase (Decrease)			Currency
											Increase (Decrease)
	BioStim	$	37,700		$	37,137			2	%		2	%
	Biologics		13,961			13,010			7	%		7	%
	Extremity Fixation		21,815			27,066			(19	)%		(9	)%
	Spine Fixation		16,286			22,801			(29	)%		(28	)%
	Total Net Sales	$	89,762		$	100,014			(10	)%		(7	)%
	The table below presents net margin, defined as gross profit less sales and marketing expenses from continuing operations by SBU reporting segment:
	Net margin by SBU	Three Months Ended
		March 31,
	(U.S. Dollars, in thousands)	2015			2014
	Net margin:
	BioStim	$	14,013		$	15,020
	Biologics		5,944			6,502
	Extremity Fixation		7,016			6,933
	Spine Fixation		(529	)		4,059
	Corporate		(306	)		(444	)
	Total net margin		26,138			32,070
	General and administrative		21,164			17,276
	Research and development		5,845			5,933
	Amortization of intangible assets		405			584
	Costs related to the accounting review and		5,916			8,306
	restatements
	Operating loss	$	(7,192	)	$	(29	)

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments And Contingencies Disclosure [Abstract]
Contingencies	11. Contingencies
	The Company is party to outstanding legal proceedings, investigations and claims, as described in (i) Part I, Item 3, “Legal Proceedings,” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014 (the “2014 Form 10-K”) and (ii) note 15 to the Company’s audited consolidated financial statements filed with the 2014 Form 10-K. The Company believes that it is unlikely that the outcome of each of these matters will have a material adverse effect on it and its subsidiaries as a whole, notwithstanding that the unfavorable resolution of any matter may have a material effect on the Company’s net earnings (if any) in any particular quarter. However, the Company cannot predict with any certainty the final outcome of any of these legal proceedings, investigations (including any settlement discussions with the government seeking to resolve such investigations) or claims, and there can be no assurance that the ultimate resolution of any such matters will not have a material adverse impact on the Company’s consolidated financial position, results of operations, or cash flows.
	The Company records accruals for certain outstanding legal proceedings, investigations or claims when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The Company evaluates, on a quarterly basis, developments in legal proceedings, investigations and claims that could affect the amount of any accrual, as well as any developments that would make a loss contingency both probable and reasonably estimable. When a loss contingency is not both probable and reasonably estimable, the Company does not accrue the loss. However, if the loss (or an additional loss in excess of the accrual) is at least a reasonable possibility and material, then the Company discloses a reasonable estimate of the possible loss or range of loss, if such reasonable estimate can be made. If the Company cannot make a reasonable estimate of the possible loss, or range of loss, then that is disclosed.
	The assessments of whether a loss is probable or a reasonable possibility, and whether the loss or range of loss is reasonably estimable, often involve a series of complex judgments about future events. Among the factors that the Company considers in this assessment are the nature of existing legal proceedings, investigations and claims, the asserted or possible damages or loss contingency (if reasonably estimable), the progress of the matter, existing law and precedent, the opinions or views of legal counsel and other advisers, the involvement of the U.S. Government and its agencies in such proceedings, the Company’s experience in similar matters and the experience of other companies, the facts available to the Company at the time of assessment, and how the Company intends to respond, or has responded, to the proceeding, investigation or claim. The Company’s assessment of these factors may change over time as individual proceedings, investigations or claims progress. For matters where the Company is not currently able to reasonably estimate the range of reasonably possible loss, the factors that have contributed to this determination include the following: (i) the damages sought are indeterminate, or an investigation has not manifested itself in a filed civil or criminal complaint, (ii) the matters are in the early stages, (iii) the matters involve novel or unsettled legal theories or a large or uncertain number of actual or potential cases or parties, and/or (iv) discussions with the government or other parties in matters that may be expected ultimately to be resolved through negotiation and settlement have not reached the point where the Company believes a reasonable estimate of loss, or range of loss, can be made. In such instances, the Company believes that there is considerable uncertainty regarding the timing or ultimate resolution of such matters, including a possible eventual loss, fine, penalty or business impact, if any.
	In addition, the Company does not accrue for estimated legal fees and other directly related costs as they are expensed as incurred.
	In addition to the matters described in the 2014 Form 10-K, in the normal course of its business, the Company is involved in various lawsuits from time to time and may be subject to certain other contingencies. To the extent losses related to these contingencies are both probable and reasonably estimable, the Company accrues appropriate amounts in the accompanying financial statements and provides disclosures as to the possible range of loss in excess of the amount accrued, if such range is reasonably estimable. The Company believes losses are individually and collectively immaterial as to a possible loss and range of loss.
	The following information supplements and amends, as applicable, the disclosures Part I, Item 3, “Legal Proceedings,” of the 2014 Form 10-K and note 15 to the Company’s audited consolidated financial statements filed with the 2014 Form 10-K:
	Securities Class Action Complaint
	The securities class action matter against the Company in the United States District Court for the Southern District of New York (No.:1:13-cv-05696-JGK), previously styled Tejinder Singh v. Orthofix International N.V., et al., is now styled Plumbers & Pipefitters National Pension Fund v. Orthofix International N.V., et al.

Nature_of_operations_basis_of_1

Nature of operations, basis of presentation and recently issues accounting pronouncements (Policies)	3 Months Ended
	Mar. 31, 2015
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Abstract]
Basis of presentation	Basis of presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Pursuant to these rules and regulations, certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, all adjustments (consisting of normal recurring items) considered necessary for a fair statement have been included. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2014. Operating results for the three months ended March 31, 2015, are not necessarily indicative of the results that may be expected for the year ending December 31, 2015. The balance sheet at December 31, 2014, has been derived from the audited financial statements at that date, but does not include all of the information and footnotes required by accounting principles generally accepted in the U.S. for complete financial statements.
	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates including those related to contractual allowances, doubtful accounts, inventories, potential goodwill and intangible asset impairment, income taxes, and shared-based compensation. Actual results could differ from these estimates. As permitted under U.S. GAAP, interim accounting for certain expenses, including income taxes, are based on full year forecasts. For interim financial reporting purposes, income taxes are recorded based upon estimated annual effective income tax rates taking into consideration discrete items occurring in a quarter.
Recently issued accounting standards	Recently issued accounting standards
	In April 2014, the FASB issued ASU 2014-08, Reporting Discontinued Operations and Disclosures of Components of an Entity. The ASU amends the definition of a discontinued operation and also provides new disclosure requirements for disposals meeting the definition, and for those that do not meet the definition, of a discontinued operation. Under the new guidance, a discontinued operation may include a component or a group of components of an entity, or a business or nonprofit activity that has been disposed of or is classified as held for sale, and represents a strategic shift that has or will have a major effect on an entity's operations and financial results. The ASU also expands the scope to include the disposals of equity method investments and acquired businesses held for sale. The guidance will be effective prospectively for interim and annual periods beginning on or after December 15, 2014, with early adoption permitted. The adoption of the guidance by the Company did not have a material impact on its consolidated financial statements.

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories were as follows:
	(U.S. Dollars, in thousands)	March 31,		December 31,
		2015		2014
	Raw materials	$	3,868	$	3,879
	Work-in-process		4,441		4,830
	Finished products		42,445		45,612
	Deferred cost of sales		5,955		5,525
	Total inventory	$	56,709	$	59,846

Derivative_instruments_Tables

Derivative instruments (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Schedule of Fair Values of Derivative Instruments	The tables below disclose the types of derivative instruments the Company owns, the classifications and fair values of these instruments within the balance sheet, and the amount of gain (loss) recognized in other comprehensive loss (“OCI”).  The ineffective portions of these instruments totaling $3.0 million and $0.1 million for the three months ended March 31, 2015 and 2014, respectively, are recognized in other income (expense).
	(U.S. Dollars, in thousands)	Fair value: favorable			Balance sheet location
	As of March 31, 2015	(unfavorable)
	Cross-currency swap	$	6,161		Other long-term assets
	Warrants	$	311		Other long-term assets
	As of December 31, 2014
	Cross-currency swap	$	2,504		Other long-term assets
	Warrants	$	321		Other long-term assets
Schedule of Gain (Loss) Recognized on Derivative Instruments
		Three Months Ended
		March 31,
	(U.S. Dollars, in thousands)	2015			2014
	Cross-currency swap unrealized gain recorded in other	$	669		$	103
	comprehensive loss, net of taxes
	Warrants unrealized loss recorded in other	$	(4	)	$	—
	comprehensive loss, net of taxes

Fair_value_measurements_Tables

Fair value measurements (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis	The fair value of the Company’s financial assets and liabilities on a recurring basis were as follows:
	(U.S. Dollars in thousands)	Balance			Level 1		Level 2			Level 3
		March 31,
		2015
	Assets
	Collective trust funds	$	1,679		$	—	$	1,679		$	—
	Treasury securities		507			507		—			—
	Certificates of deposit		1,260			1,260		—			—
	Derivative securities		6,472			—		6,472			—
	Equity securities		1,457			—		1,457			—
	Debt securities		15,000			—		—			15,000
	Total	$	26,375		$	1,767	$	9,608		$	15,000
	Liabilities
	Deferred compensation plan	$	(1,488	)	$	—	$	(1,488	)	$	—
	Total	$	(1,488	)	$	—	$	(1,488	)	$	—
	(U.S. Dollars in thousands)	Balance			Level 1		Level 2			Level 3
		December 31,
		2014
	Assets
	Collective trust funds	$	1,696		$	—	$	1,696		$	—
	Treasury securities		586			586		—			—
	Certificates of deposit		1,510			1,510		—			—
	Derivative securities		2,825			—		2,825			—
	Equity securities		1,457			—		1,457			—
	Total	$	8,074		$	2,096	$	5,978		$	—
	Liabilities
	Deferred compensation plan	$	(1,886	)	$	—	$	(1,886	)	$	—
	Total	$	(1,886	)	$	—	$	(1,886	)	$	—
Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Schedule of Reconciliation of Available for Sale Debt Securities	The following table provides a reconciliation of the beginning and ending balances for the debt securities measured at fair value using significant unobservable inputs (Level 3):
	(U.S. Dollars in thousands)	2015
	Balance at January 1	$	—
	Additions to debt securities		15,000
	Balance at March 31	$	15,000

Accumulated_other_comprehensiv1

Accumulated other comprehensive income (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Components of Changes in Accumulated Other Comprehensive Loss	The components of and changes in accumulated other comprehensive loss were as follows
	(U.S. Dollars, in thousands)		Foreign Currency			Change		Accumulated Other
			Translation Adjustments			in		Comprehensive Loss
						Fair Value
	Balance at December 31, 2014		$	(482	)	$	100	$	(382	)
	Unrealized gain on cross-currency swap and warrants,			—			665		665
	net of tax of $435
	Foreign currency translation adjustment (1)			(4,860	)		—		(4,860	)
	Balance at March 31, 2015		$	(5,342	)	$	765	$	(4,577	)
	-1	As the unremitted earnings generally remain indefinitely reinvested in the non U.S. dollar denominated foreign subsidiaries, no deferred taxes are recognized on the related foreign currency translation adjustment.

Earnings_per_share_Tables

Earnings per share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Reconciliation of Weighted Average Shares Used in Calculation of Basic and Diluted Earnings Per Share	The following is a reconciliation of the weighted average shares used in the basic and diluted net loss per common share computations.
		Three Months Ended
		March 31,
		2015		2014
	Weighted average common shares-basic		18,731,985		18,197,363
	Effect of dilutive securities:
	Unexercised stock options net of treasury share		—		—
	repurchase
	Weighted average common shares-diluted		18,731,985		18,197,363

Sharebased_compensation_Tables

Share-based compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Share-Based Compensation by Line Item in Consolidated Statements of Operations	The following table shows the detail of share-based compensation by line item in the condensed consolidated statements of operations:
		Three Months Ended
		March 31,
	(U.S. Dollars, in thousands)	2015		2014
	Cost of sales	$	111	$	29
	Sales and marketing		306		444
	General and administrative		1,269		642
	Research and development		91		72
	Total	$	1,777	$	1,187

Business_segment_information_T

Business segment information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of Net Sales by SBU Reporting Segment	The table below presents net sales for continuing operations by SBU reporting segment. Net sales include product sales and marketing service fees. Marketing service fees, which are recorded on a net basis, are comprised of fees earned for the marketing of Trinity Evolution®, Trinity ELITE® and Versashield™ in our Biologics segment.
		Net Sales by SBU
		Three Months Ended March 31,
	(U.S. Dollars, in thousands)	2015			2014			Reported			Constant
								Increase (Decrease)			Currency
											Increase (Decrease)
	BioStim	$	37,700		$	37,137			2	%		2	%
	Biologics		13,961			13,010			7	%		7	%
	Extremity Fixation		21,815			27,066			(19	)%		(9	)%
	Spine Fixation		16,286			22,801			(29	)%		(28	)%
	Total Net Sales	$	89,762		$	100,014			(10	)%		(7	)%
Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment	The table below presents net margin, defined as gross profit less sales and marketing expenses from continuing operations by SBU reporting segment:
	Net margin by SBU	Three Months Ended
		March 31,
	(U.S. Dollars, in thousands)	2015			2014
	Net margin:
	BioStim	$	14,013		$	15,020
	Biologics		5,944			6,502
	Extremity Fixation		7,016			6,933
	Spine Fixation		(529	)		4,059
	Corporate		(306	)		(444	)
	Total net margin		26,138			32,070
	General and administrative		21,164			17,276
	Research and development		5,845			5,933
	Amortization of intangible assets		405			584
	Costs related to the accounting review and		5,916			8,306
	restatements
	Operating loss	$	(7,192	)	$	(29	)

Nature_of_operations_basis_of_2

Nature of operations, basis of presentation and recently issues accounting pronouncements - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Abstract]
Number Of Reporting Units	4

Inventories_Schedule_of_Invent

Inventories - Schedule of Inventories (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw materials	$3,868	$3,879
Work-in-process	4,441	4,830
Finished products	42,445	45,612
Deferred cost of sales	5,955	5,525
Total inventory	$56,709	$59,846

LongTerm_Debt_Additional_Infor

Long-Term Debt - Additional Information (Detail)	Mar. 31, 2015	Jan. 15, 2015	Dec. 31, 2014	Dec. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Aug. 30, 2010	Aug. 30, 2010	Mar. 31, 2015
	USD ($)	USD ($)	USD ($)	EUR (€)	Revolving Credit Facility [Member]	Revolving Credit Facility [Member]	Revolving Credit Facility [Member]	Term Loan Facility [Member]	Term Loan Facility [Member]
					USD ($)	USD ($)	USD ($)	USD ($)
Debt Instrument [Line Items]
Debt instrument term (in years)					5 years				5 years
Maximum borrowing capacity	$6,200,000		$7,000,000	€ 5,800,000			$200,000,000
Maximum borrowing capacity								100,000,000
Available capacity under the revolving credit facility		100,000,000
Amount outstanding under lines of credit	0				0	0
Revolving credit facility due date					30-Aug-15
Amount of restricted net assets	184,100,000		181,800,000
Restricted cash	$27,253,000		$34,424,000

Derivative_Instruments_Additio

Derivative Instruments - Additional Information (Detail) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Ineffective portion of derivative instrument recognized in other income (expense)	$3	$0.10

Derivative_Instruments_Schedul

Derivative Instruments - Schedule of Fair Values of Derivative Instruments (Detail) (Other long-term Assets [Member], USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Cross-Currency Swap [Member]
Derivatives Fair Value [Line Items]
Fair value: favorable (unfavorable)	$6,161	$2,504
Warrants [Member]
Derivatives Fair Value [Line Items]
Fair value: favorable (unfavorable)	$311	$321

Derivative_Instruments_Schedul1

Derivative Instruments - Schedule of Gain (Loss) Recognized on Derivative Instruments (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Derivative Instruments [Line Items]
Cross-currency swap unrealized gain recorded in other comprehensive loss, net of taxes	$665	$103
Cross-Currency Swap [Member]
Derivative Instruments [Line Items]
Cross-currency swap unrealized gain recorded in other comprehensive loss, net of taxes	669	103
Warrants [Member]
Derivative Instruments [Line Items]
Cross-currency swap unrealized gain recorded in other comprehensive loss, net of taxes	($4)

Fair_Value_Measurements_Schedu

Fair Value Measurements - Schedule of Financial Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Inputs, Level 3 [Member] | Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	$15,000
Fair Value, Measurements, Recurring [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	26,375	8,074
Deferred compensation plan, Liabilities	-1,488	-1,886
Liabilities fair value, Total	-1,488	-1,886
Fair Value, Measurements, Recurring [Member] | Collective Trust Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	1,679	1,696
Fair Value, Measurements, Recurring [Member] | Treasury Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	507	586
Fair Value, Measurements, Recurring [Member] | Certificates of Deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	1,260	1,510
Fair Value, Measurements, Recurring [Member] | Derivative Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	6,472	2,825
Fair Value, Measurements, Recurring [Member] | Equity Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	1,457	1,457
Fair Value, Measurements, Recurring [Member] | Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	15,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	1,767	2,096
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Treasury Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	507	586
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Certificates of Deposit [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	1,260	1,510
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	9,608	5,978
Deferred compensation plan, Liabilities	-1,488	-1,886
Liabilities fair value, Total	-1,488	-1,886
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Collective Trust Funds [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	1,679	1,696
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Derivative Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	6,472	2,825
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Equity Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	1,457	1,457
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	15,000
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Debt Securities [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Assets fair value	$15,000

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (eNeura Inc [Member], USD $)	0 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Mar. 04, 2015	Mar. 31, 2015
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Non-refundable fees paid	$0.30
Accrued interest on promissory note	8.00%
Maturity description of Promissory note		The eNeura Note will mature on the earlier of (i) March 4, 2019, or (ii) exercise of the Option.
Debt Instrument, Maturity Date		4-Mar-19
Convertible Debt Securities
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Principal amount of promissory note	$15

Fair_Value_Measurements_Schedu1

Fair Value Measurements - Schedule of Reconciliation of Debt Securities (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Additions to debt securities	$15,250
Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Additions to debt securities	15,000
Ending balance	$15,000

Accumulated_other_comprehensiv2

Accumulated other comprehensive loss - Components of Changes in Accumulated Other Comprehensive Loss (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	($382)
Unrealized gain on cross-currency swap and warrants, net of tax	665	103
Foreign currency translation adjustment	-4,860	376
Ending Balance	-4,577
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	-482
Foreign currency translation adjustment	-4,860
Ending Balance	-5,342
Change in Fair Value [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance			100
Ending Balance	765		100
Change in Fair Value [Member] | Cross-Currency Swap and Warrants [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized gain on cross-currency swap and warrants, net of tax	665
Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Beginning Balance	-382
Foreign currency translation adjustment	-4,860
Ending Balance	-4,577
Accumulated Other Comprehensive Loss [Member] | Cross-Currency Swap and Warrants [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized gain on cross-currency swap and warrants, net of tax	$665

Accumulated_other_comprehensiv3

Accumulated other comprehensive loss - Components of Changes in Accumulated Other Comprehensive Loss (Parenthetical) (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Deferred taxes recognized on related foreign currency translation adjustment	$0
Cross-Currency Swap and Warrants [Member] | Change in Fair Value [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized gain on cross-currency swap and warrants, net of tax	435,000
Cross-Currency Swap and Warrants [Member] | Accumulated Other Comprehensive Loss [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized gain on cross-currency swap and warrants, net of tax	$435,000

Earnings_Per_Share_Schedule_of

Earnings Per Share - Schedule of Reconciliation of Weighted Average Shares Used in Calculation of Basic and Diluted Earnings Per Share (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Earnings Per Share [Abstract]
Weighted average common shares-basic	18,731,985	18,197,363
Effect of dilutive securities:
Weighted average common shares-diluted	18,731,985	18,197,363

Earnings_Per_Share_Additional_

Earnings Per Share - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Outstanding options not included in diluted earnings per share	894,565	1,691,203
Common Stock Equivalents [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Outstanding options not included in diluted earnings per share	182,266	30,719

Sharebased_Compensation_Schedu

Share-based Compensation - Schedule of Share-Based Compensation by Line Item in Consolidated Statements of Operations (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$1,777,000	$1,187,000
Cost of sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	111,000	29,000
Sales and marketing [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	306,000	444,000
General and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	1,269,000	642,000
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share based compensation expense	$91,000	$72,000

Sharebased_Compensation_Additi

Share-based Compensation - Additional Information (Detail) (USD $)	3 Months Ended		0 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Mar. 31, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense recognized	$1,777,000	$1,187,000
Shares issued under stock purchase plan	153,367	263,575
Restricted Stock [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense recognized			$0

Income_Taxes_Additional_Inform

Income Taxes - Additional Information (Detail) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Provision for income tax	$964,000	$1,179,000
Income tax effective rate	-14.20%	-153.30%
Income tax effective rate excluding the impact of discrete charges	-9.20%	-68.50%
Gross unrecognized tax benefit	15,600,000		15,600,000
Accrued interest and penalties related to unrecognized tax benefits	$500,000		$500,000

Business_Segment_Information_A

Business Segment Information - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2015
	Segment
Segment Reporting [Abstract]
Number of strategic business units	4

Business_Segment_Information_S

Business Segment Information - Schedule of Net Sales by SBU Reporting Segment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Sales Information [Line Items]
Net Sales	$89,762	$100,014
Reported Increase (Decrease) (as percent)	-10.00%
Constant Currency Increase (Decrease) (as percent)	-7.00%
BioStim [Member]
Sales Information [Line Items]
Net Sales	37,700	37,137
Reported Increase (Decrease) (as percent)	2.00%
Constant Currency Increase (Decrease) (as percent)	2.00%
Biologics [Member]
Sales Information [Line Items]
Net Sales	13,961	13,010
Reported Increase (Decrease) (as percent)	7.00%
Constant Currency Increase (Decrease) (as percent)	7.00%
Extremity Fixation [Member]
Sales Information [Line Items]
Net Sales	21,815	27,066
Reported Increase (Decrease) (as percent)	-19.00%
Constant Currency Increase (Decrease) (as percent)	-9.00%
Spine Fixation [Member]
Sales Information [Line Items]
Net Sales	$16,286	$22,801
Reported Increase (Decrease) (as percent)	-29.00%
Constant Currency Increase (Decrease) (as percent)	-28.00%

Business_Segment_Information_S1

Business Segment Information - Summary of Net Margin, Defined as Gross Profit Less Sales and Marketing Expenses from Continuing Operations by SBU Reporting Segment (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Segment Reporting Information [Line Items]
Total net margin	$26,138	$32,070
General and administrative	21,164	17,276
Research and development	5,845	5,933
Amortization of intangible assets	405	584
Costs related to the accounting review and restatements	5,916	8,306
Operating loss	-7,192	-29
Operating Segments [Member] | BioStim [Member]
Segment Reporting Information [Line Items]
Total net margin	14,013	15,020
Operating Segments [Member] | Biologics [Member]
Segment Reporting Information [Line Items]
Total net margin	5,944	6,502
Operating Segments [Member] | Extremity Fixation [Member]
Segment Reporting Information [Line Items]
Total net margin	7,016	6,933
Operating Segments [Member] | Spine Fixation [Member]
Segment Reporting Information [Line Items]
Total net margin	-529	4,059
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Total net margin	-306	-444
Material Reconciling Items [Member]
Segment Reporting Information [Line Items]
General and administrative	21,164	17,276
Research and development	5,845	5,933
Amortization of intangible assets	405	584
Costs related to the accounting review and restatements	$5,916	$8,306